- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07469891
Un estudio de Fase 1 de PRT12396 en participantes con neoplasias mieloproliferativas seleccionadas
Un Estudio de Fase 1, Abierto, Multicéntrico, de Seguridad y Eficacia de PRT12396 en Participantes con Policitemia Vera y Mielofibrosis
This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
This first-in-human, open-label, multi-center Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF). Eligible MF populations include participants with intermediate-1, intermediate-2, or high-risk primary MF, as well as post-polycythemia vera MF or post-essential thrombocythemia MF, with evidence of disease burden based on splenomegaly.
The study is conducted in two parts:
Part 1 (dose escalation) evaluates escalating oral doses of PRT12396 to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]).
Part 2 (dose expansion) enrolls additional participants at selected dose level(s) to further characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in the PV and MF populations.
Approximately up to 100 participants are planned for enrollment across both parts of the study.
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Study Contact (Please Do Not Disclose Personal Information)
- Número de teléfono: See Email
- Correo electrónico: clinicaltrials@preludetx.com
Ubicaciones de estudio
-
-
South Australia
-
Adelaide, South Australia, Australia, 5000
- Reclutamiento
- Royal Adelaide Hospital
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Reclutamiento
- Monash Health, Monash Medical Centre
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Reclutamiento
- One Clinical Research
-
-
-
-
-
Barcelona, España, 08036
- Reclutamiento
- Hospital Clinic de Barcelona
-
Madrid, España, 28034
- Reclutamiento
- Hospital Universitario Ramon y Cajal
-
Madrid, España, 28041
- Reclutamiento
- Hospital Universitario 12 de Octubre
-
Valencia, España, 46010
- Reclutamiento
- Hospital Clínico Universitario de Valencia
-
-
-
-
California
-
Los Angeles, California, Estados Unidos, 90095
- Reclutamiento
- UCLA Ronald Reagan Medical Center
-
Sacramento, California, Estados Unidos, 95817
- Reclutamiento
- University of California, Davis Comprehensive Cancer Center
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80218
- Reclutamiento
- Colorado Blood Cancer Institute
-
-
Florida
-
Coral Springs, Florida, Estados Unidos, 33065
- Reclutamiento
- BRCR Global - Coral Springs
-
Miami, Florida, Estados Unidos, 33136
- Reclutamiento
- Sylvester Comprehensive Cancer Center
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt Cancer Center
-
-
Michigan
-
Grand Rapids, Michigan, Estados Unidos, 49546
- Reclutamiento
- START Midwest, LLC
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19107
- Reclutamiento
- Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- Tristar BMT
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- Tennessee Oncology, PLLC - Investigational Drug Services
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- The University of Texas, MD Anderson Cancer Center
-
-
-
-
-
Nice, Francia, 06200
- Reclutamiento
- Nice University Medicâl Center (CHU Nice, Hôpital Archet 1)
-
Paris, Francia, 75010
- Reclutamiento
- Saint-Louis Hospital
-
Toulouse, Francia, 31059
- Reclutamiento
- Oncopole Claudius Regaud
-
-
-
-
-
Florence, Italia, 50134
- Reclutamiento
- Azienda Ospedaliero Universitaria Careggi
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures.
- Confirmed diagnosis of PV or MF according to WHO 2016 or revised ICC/WHO 2022 criteria
- Documented presence of a JAK2 V617 mutation
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
- Estimate life expectancy of ≥12 weeks per investigator assessment.
- Negative serum or urine pregnancy test and agree to use contraception or maintain true abstinence.
- Adequate organ function and bone marrow reserves (hematology, renal, and hepatic)
Exclusion Criteria:
- History of another malignancy within 3 years prior to enrollment, except for malignancy considered cured with low risk of recurrence.
- Clinically significant anemia due to nutritional deficiency or hemolytic disorders.
- Active or uncontrolled infection requiring systemic therapy or hospitalization.
- Any other medical or psychiatric conditions that, in the Investigator's judgment, would increase risk or interfere with study participation or interpretation of results.
- Clinically significant or uncontrolled medical conditions, including active infection or cardiovascular disease, that would increase risk or interfere with study participation.
- Unresolved toxicity Grade >1 from prior anticancer therapy, except for alopecia or peripheral neuropathy Grade ≤2.
- Pregnancy or breastfeeding
- Known sensitivity or contraindication to any component of study, or the excipients of study treatment.
- Prior systemic therapy for PV or MF, prior or planned allogeneic hematopoietic stem-cell transplantation, recent major surgery, prior splenectomy or prior splenic irradiation, or use of hematopoietic growth factors within protocol-defined washout periods.
- Use of strong or moderate cytochrome P450 (CYP) 3A4 inhibitor or inducer, sensitive CYP3A substrates with narrow therapeutic range, or acid-reducing agents that cannot be discontinued prior to study treatment.
- Participation in another interventional clinical study.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: PRT12396: MF
Participants with myelofibrosis receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE) |
PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals. |
|
Experimental: PRT12396: PV
Participants with polycythemia vera receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE) |
PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Dose limiting toxicity (DLT) of PRT12396
Periodo de tiempo: Through cycle 1 (4 weeks)
|
Incidence of dose limiting toxicities, defined according to protocol-specified criteria |
Through cycle 1 (4 weeks)
|
|
Incidence and severity of Adverse events
Periodo de tiempo: Through study completion, an average of 2 years
|
Incidence and severity of treatment-emergent adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 6.0 |
Through study completion, an average of 2 years
|
|
Adverse Events Leading to Dose Modifications or Discontinuation
Periodo de tiempo: Through study completion, an average of 2 years
|
Incidence of AEs leading to dose reductions, dose interruptions, treatment discontinuations, and clinically significant laboratory abnormalities |
Through study completion, an average of 2 years
|
|
Maximum tolerated dose (MTD) and Recommended Dose(s) for Expansion (RDE[s]) of PRT12396
Periodo de tiempo: Through study completion, an average of 2 years
|
Determination of the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]) based on evaluation of DLTs, safety, and tolerability data |
Through study completion, an average of 2 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Hematologic Response Rate (PV)
Periodo de tiempo: Through study completion, an average of 2 years
|
Proportion of participants with polycythemia vera (PV) achieving best overall hematologic response (complete hematologic response or partial hematologic response) from the overall response assessments by Investigator |
Through study completion, an average of 2 years
|
|
Duration of Hematologic Response (PV)
Periodo de tiempo: Through study completion, an average of 2 years
|
Duration of hematologic response in PV participants, defined as the time from first documented response (best overall hematologic response) to disease progression or death, whichever comes first |
Through study completion, an average of 2 years
|
|
Hematocrit Control Without Phlebotomy Requirements (PV)
Periodo de tiempo: Through study completion, an average of 2 years
|
Proportion of PV participants achieving and maintaining hematocrit control without phlebotomy, time to first phlebotomy, and frequency of phlebotomy |
Through study completion, an average of 2 years
|
|
Spleen Response (MF)
Periodo de tiempo: Through study completion, an average of 2 years
|
Assessment of spleen response including proportion achieving protocol-specified reduction in spleen volume, time to spleen response, duration of spleen response, and reduction in palpable spleen length |
Through study completion, an average of 2 years
|
|
Change from Baseline in Hemoglobin (MF)
Periodo de tiempo: Through study completion, an average of 2 years
|
Change from baseline in hemoglobin levels in MF participants |
Through study completion, an average of 2 years
|
|
Change from Baseline in Platelet Count (MF)
Periodo de tiempo: Through study completion, an average of 2 years
|
Change from baseline in platelet count in MF participants |
Through study completion, an average of 2 years
|
|
Change from Baseline in Absolute Neutrophil Count (MF)
Periodo de tiempo: Through study completion, an average of 2 years
|
Change from baseline in absolute neutrophil count in MF participants |
Through study completion, an average of 2 years
|
|
Transfusion Independence (MF)
Periodo de tiempo: Through study completion, an average of 2 years
|
Proportion achieving transfusion independence and duration of transfusion independence as defined by protocol criteria |
Through study completion, an average of 2 years
|
|
Maximum Observed Plasma Concentration (Cmax)
Periodo de tiempo: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Maximum observed plasma concentration will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Time To Maximum Concentration (Tmax)
Periodo de tiempo: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Time to maximum concentration will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Area under the plasma concentration versus time curve (AUC)
Periodo de tiempo: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Area under the plasma concentration-time curve will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Terminal Elimination Half-life (T1/2)
Periodo de tiempo: Cycle 1 Day 1
|
Terminal elimination half-life will be calculated using non-compartmental analysis |
Cycle 1 Day 1
|
|
Steady State Trough Concentrations
Periodo de tiempo: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Steady state trough concentrations will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Clearance
Periodo de tiempo: Cycle 1 Day 1
|
Clearance will be calculated using non-compartmental analysis |
Cycle 1 Day 1
|
|
Accumulation
Periodo de tiempo: Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
Accumulation will be calculated using non-compartmental analysis |
Up to Cycle 4 Day 1 (each cycle is 4 weeks)
|
|
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
Periodo de tiempo: Through study completion, an average of 2 years
|
Patient-reported outcomes assessed using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), evaluated as change from baseline at protocol-specified time points. The MPN SAF TSS is a validated questionnaire in which individual symptoms are scored using a numeric rating scale ranging from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst imaginable symptoms; higher scores indicate greater symptom severity. |
Through study completion, an average of 2 years
|
|
Patient Global Impression of Change (PGI-C)
Periodo de tiempo: Through study completion, an average of 2 years
|
Participant reported outcomes assessed using the Patient Global Impression of Change (PGI-C), evaluated at protocol-specified time points. The PGI C is a global assessment scale in which participants rate their overall change in condition since baseline using a 7 point ordinal scale ranging from "very much improved" to "very much worse," with lower scores indicating improvement and higher scores indicating worsening of symptoms. |
Through study completion, an average of 2 years
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- PRT12396-01
- 2026-525484-40-00 (Ctis)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .